A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Public ClinicalTrials.gov record NCT01009775. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage IV melanoma.
Study identification
- NCT ID
- NCT01009775
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 64 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Aug 2012 (Actual)
- Last update posted
- Sep 4, 2015
2009 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama | Mobile | Alabama | 36604 | — |
| University of South Alabama | Mobile | Alabama | 36619/36604 | — |
| Arizona Clinical Research Center | Tuscon | Arizona | 85715 | — |
| The Angeles Clinic and Research | Los Angeles | California | 90025 | — |
| UCLA | Los Angeles | California | 90095 | — |
| Redwood Regional Medical Group | Sebastopol | California | 95472 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Univ. of Michigan Health System | Ann Arbor | Michigan | 48105 | — |
| Univ. of Michigan Health System | Ann Arbor | Michigan | 48109/48109 | — |
| St. Lukes Hospital Cancer Center | Bethlehem | Pennsylvania | 18015 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01009775, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2015 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01009775 live on ClinicalTrials.gov.